A phase 2 study of GVAX colon vaccine with cyclophosphamide and pembrolizumab in patients with mismatch repair proficient advanced colorectal cancer.

Mark YarchoanChiung-Yu HuangQingfeng ZhuAnna K FergusonJennifer N DurhamRobert A AndersElizabeth D ThompsonNoah S RozichDwayne L ThomasJulie M NaurothChristina RodriguezArsen OsipovAna De Jesus-AcostaDung T LeAdrian G MurphyDaniel LaheruRoss C DonehowerElizabeth M JaffeeLei ZhengNilofer S Azad

Published in: Cancer medicine (2019)

GVAX/Cy plus pembrolizumab failed to meet its primary objective in MMRp CRC. Biochemical responses were observed in a subset of patients and have not previously been observed with pembrolizumab monotherapy in MMRp CRC, indicating that GVAX may modulate the antitumor immune response.

Keyphrases

immune response
advanced non small cell lung cancer
end stage renal disease
ejection fraction
open label
newly diagnosed
low dose
prognostic factors
peritoneal dialysis
randomized controlled trial
clinical trial
patient reported outcomes
inflammatory response